UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study ...